Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Friendly Fire

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Jun 11, 2021 2:55pm

213 Views

Post# 33373527

RE:Friendly Fire

As some may know, I'm not a huge fan of how Dan has run this company, but in this situation, I don't think Dan/Board Head selling had that big of an impact. If something were truly wrong, the entire management team would sell big chunks of stock. It's unrealistic to think these guys have to hang onto every single share. He sold 75,000 so that he could pay for something. Big deal. He still has a boatload. I still believe in the science.